Roger Adsett Sells 791 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 791 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $16,680,517.70. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $140,406.14.
• On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $247,688.57.

Insmed Stock Down 0.9%

INSM opened at $151.03 on Friday. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The firm’s fifty day moving average price is $176.03 and its two-hundred day moving average price is $159.60. The company has a market capitalization of $32.21 billion, a P/E ratio of -24.40 and a beta of 1.11.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Large institutional holders remain significant and have been increasing positions, which supports structural demand and can limit downside. MarketBeat Institutional Holdings
• Positive Sentiment: Analyst coverage is strongly skewed to Buy/Strong Buy with an average price target well above the current trading level, implying upside if upcoming results and guidance meet expectations. MarketBeat Analyst Coverage
• Neutral Sentiment: Insmed set its Q4 and full‑year 2025 results release and conference call for Feb. 19 — a concrete near‑term catalyst that will provide revenue, margin and guidance data investors will use to re‑rate the stock. PR Newswire: Earnings Date
• Negative Sentiment: Clustered insider sales: multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and another officer) sold shares on Feb. 3. Such concentrated selling by leadership can be interpreted negatively and likely contributed to intraday weakness. InsiderTrades: Insider Sales
• Negative Sentiment: Pattern risk: the CFO and other officers had earlier sales in January, creating a sequence of executive trims this quarter rather than isolated trades; that pattern may increase short‑term selling pressure or investor caution ahead of Feb. 19. SEC Form 4 (CEO/CFO Sales)

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on INSM shares. Wedbush set a $203.00 price objective on Insmed in a report on Thursday, December 18th. Wells Fargo & Company set a $195.00 price target on Insmed in a research note on Thursday, December 18th. Bank of America upped their price target on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Guggenheim cut their price objective on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Finally, Mizuho set a $212.00 target price on shares of Insmed in a research note on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $206.04.

Hedge Funds Weigh In On Insmed

A number of institutional investors and hedge funds have recently bought and sold shares of the business. EULAV Asset Management bought a new position in shares of Insmed in the 3rd quarter worth $12,961,000. Resolute Capital Asset Partners LLC acquired a new position in Insmed in the second quarter valued at about $2,748,000. Nisa Investment Advisors LLC boosted its holdings in Insmed by 374.6% during the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock worth $1,507,000 after buying an additional 8,261 shares during the last quarter. Calamos Advisors LLC boosted its holdings in Insmed by 53.4% during the third quarter. Calamos Advisors LLC now owns 35,215 shares of the biopharmaceutical company’s stock worth $5,071,000 after buying an additional 12,263 shares during the last quarter. Finally, Guggenheim Capital LLC grew its position in shares of Insmed by 16.8% during the 2nd quarter. Guggenheim Capital LLC now owns 41,391 shares of the biopharmaceutical company’s stock worth $4,166,000 after buying an additional 5,945 shares during the period.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.